JewishStatusOpen the app

Jewish News 24 · Aug 13, 2026

Jewish News 24 — photo status

Israeli startup Remepy has raised $36 million in Series A funding, backed in part by Merck's venture arm M Ventures, to advance its Al-powered Parkinson's treatment into a global Phase III trial. The Hybridopa approach combines standard medication with personalized app-based therapy, following Phase lla results that showed significant improvements in motor and non-motor symptoms. The Phase III program is expected to begin in Q4 2026.

Israeli startup Remepy has raised $36 million in Series A funding, backed in part by Merck's venture arm M Ventures, to advance its Al-powered Parkinson's treatment into a global Phase III trial. The Hybridopa approach combines standard medication with personalized app-based therapy, following Phase lla results that showed significant improvements in motor and non-motor symptoms. The Phase III program is expected to begin in Q4 2026.

Watch in the app All of Jewish News 24's statuses

More from Jewish News 24